A071701 Genomically-Guided Treatment Trial in Brain Metastases

A071701 Genomically-Guided Treatment Trial in Brain Metastases
Recruiting
18 years - 99 years
All
Phase N/A
3 participants needed
1 Location

Brief description of study

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Brain Metastases,Brain Tumor,Brain Metastases, Brain Tumor
  • Age: 18 years - 99 years
  • Gender: All

Male and Female 18 years of age and older Brain Tumor

Updated on 04 Aug 2024. Study ID: 849264

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center